Viatris Inc
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
The complaint alleges that the defendants, during the specified period, made false and misleading statements. The plaintiff claims that the defendants failed to disclose several important factors, including increased competition in the company’s US complex generics business, the inability to manage base business erosion and create a stable revenue base, the plan to divest the biosimilars business to meet phase one goals, a significant global reshaping of the business that would undermine revenue growth, and anticipated lower financial growth in 2022.
On February 28, 2022, the defendants announced the sale of the biosimilars business to Biocon Biologics Limited, with the closing expected in the second half of 2022. The company also revealed its intention to divest additional business assets and undergo a significant global reshaping.
As a result of this news, Viatris’ stock price experienced a sharp decline of $3.53, representing a decrease of more than 24%, and closed at $11.01 per share on February 28, 2022.
